Mark A. Varney
Founder at Neurolixis, Inc.
Mark A. Varney active positions
Companies | Position | Start | End |
---|---|---|---|
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Director/Board Member | - | - |
Founder | - | - |
Career history of Mark A. Varney
Former positions of Mark A. Varney
Companies | Position | Start | End |
---|---|---|---|
RESPIRERX PHARMACEUTICALS INC. | Director/Board Member | 2006-01-29 | 2013-03-21 |
Investor Relations Contact | 2011-06-15 | 2013-03-21 | |
Public Communications Contact | 2010-07-28 | 2013-03-21 | |
President | 2006-01-29 | 2013-03-21 | |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 2004-05-31 | 2005-12-31 |
BIONOMICS LIMITED | Corporate Officer/Principal | 2004-05-31 | 2004-05-31 |
MERCK & CO., INC. | Corporate Officer/Principal | 1999-08-31 | 2003-03-31 |
Sibia Neurosciences, Inc. | Corporate Officer/Principal | 1994-09-30 | 1999-08-31 |
Training of Mark A. Varney
University of Surrey | Undergraduate Degree |
University of Oxford | Doctorate Degree |
Statistics
International
United States | 6 |
United Kingdom | 3 |
Australia | 2 |
Operational
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Investor Relations Contact | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
RESPIRERX PHARMACEUTICALS INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
BIONOMICS LIMITED | Health Technology |
Private companies | 3 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Sibia Neurosciences, Inc. | Health Technology |
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Mark A. Varney
- Experience